title: Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
abstract: Mutations of the BRCA1 or BRCA2 genes have been shown to strongly predispose towards the development of contralateral breast cancer in patients from large multi-case families. In order to test the hypothesis that BRCA1 and BRCA2 mutations are more frequent in patients with bilateral breast cancer, we have investigated a hospital-based series of 75 consecutive patients with bilateral breast cancer and a comparison group of 75 patients with unilateral breast cancer, pairwise matched by age and family history, for mutations in the BRCA1 and BRCA2 genes. Five frameshift deletions (517delGT in BRCA1; 4772delA, 5946delCT, 6174delT and 8138del5 in BRCA2) were identified in patients with bilateral disease. No further mutations, apart from polymorphisms and 3 rare unclassified variants, were found after scanning the whole BRCA1 and BRCA2 coding sequence. Three pathogenic BRCA1 mutations (Cys61Gly, 3814del5, 5382insC) were identified in the group of patients with unilateral breast cancer. The frequencies of common BRCA1 and BRCA2 missense variants were not different between the 2 groups. In summary, we did not find a significantly increased prevalence of BRCA1 and BRCA2 mutations in a hospital-based cohort of German patients with bilateral breast cancer. We conclude that bilaterality of breast cancer on its own is not strongly associated with BRCA1 and BRCA2 mutations when adjusted for age and family history. The high frequency of bilateral disease in multi-case breast cancer families may be due to a familial aggregation of additional susceptibility factors modifying the penetrance of BRCA1 and BRCA2 mutations.
authors.affiliation: Department of Radiation Oncology, Institute of Human Genetics, Medical School Hannover, Hannover, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Steinmann
authors.forename: M
authors.initials: M
authors.lastname: Bremer
authors.forename: D
authors.initials: D
authors.lastname: Rades
authors.forename: B
authors.initials: B
authors.lastname: Skawran
authors.forename: C
authors.initials: C
authors.lastname: Siebrands
authors.forename: J H
authors.initials: JH
authors.lastname: Karstens
authors.forename: T
authors.initials: T
authors.lastname: Dörk
mesh_terms: D000328:Adult; D000368:Aged; D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000532:radiotherapy; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000235:genetics* / Q000532:radiotherapy; D004252:DNA Mutational Analysis; D017931:DNA Primers / Q000737:chemistry; D004262:DNA Restriction Enzymes; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D019398:Genes, BRCA1 / Q000235:genetics*; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D009361:Neoplasm Invasiveness / Q000235:genetics*; D009363:Neoplasm Proteins / Q000235:genetics*; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D011795:Surveys and Questionnaires; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D024682:BRCA2 Protein; D017931:DNA Primers; D004273:DNA, Neoplasm; D005819:Genetic Markers; D009363:Neoplasm Proteins; D014157:Transcription Factors; D004262:DNA Restriction Enzymes